Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by Engcan77on Apr 27, 2017 9:43pm
196 Views
Post# 26177338

RE:RE:RE:RE:RE:Mistakes

RE:RE:RE:RE:RE:MistakesI agree with many points made here. There could be another CEO brought in after the skin lightener deal. The deal will attract more candidates,hopefully. The best scenario for stock holders is an eventual buyout, and that is one reason I will hold a big chunk of my shares. Another is the vast array  of other products that SBM should be producing in the coming years. The quicker they can sign the first deal, the quicker they can start pushing the others. Not once has management said that they want a decrease upfront payments, that I can recollect. It was someone on the board that would be happy with less just to get the deal done. Who knows what the final agreement would be. I believe it was a mistake by management to put out a number before it was actually signed. Maybe 'up to 90 million' would have better. Hindsight is 20/20. It sounds like they wanted that amount or would go alone. There's probably not many managers out there that haven't made mistakes.All the remaining SBM management can do is move on and hopefully learn from those mistakes. I must admit they have a long way to go to regain my confidence. Closing big deals and follow through on ones that have been signed on great products,(maybe sometimes out of their control) and quit setting dates that can't be met. Frustrating for everyone!

Bullboard Posts